155 related articles for article (PubMed ID: 38329728)
21. The CHK1 inhibitor SRA737 synergizes with PARP1 inhibitors to kill carcinoma cells.
Booth L; Roberts J; Poklepovic A; Dent P
Cancer Biol Ther; 2018; 19(9):786-796. PubMed ID: 30024813
[TBL] [Abstract][Full Text] [Related]
22. Neratinib decreases pro-survival responses of [sorafenib + vorinostat] in pancreatic cancer.
Booth L; Poklepovic A; Dent P
Biochem Pharmacol; 2020 Aug; 178():114067. PubMed ID: 32504550
[TBL] [Abstract][Full Text] [Related]
23. Rationally Repurposing Ruxolitinib (Jakafi (®)) as a Solid Tumor Therapeutic.
Tavallai M; Booth L; Roberts JL; Poklepovic A; Dent P
Front Oncol; 2016; 6():142. PubMed ID: 27379204
[TBL] [Abstract][Full Text] [Related]
24. (Curcumin+sildenafil) enhances the efficacy of 5FU and anti-PD1 therapies in vivo.
Dent P; Booth L; Roberts JL; Poklepovic A; Hancock JF
J Cell Physiol; 2020 Oct; 235(10):6862-6874. PubMed ID: 31985048
[TBL] [Abstract][Full Text] [Related]
25. Potent Antitumor Effects of a Combination of Three Nutraceutical Compounds.
Vishwakarma V; New J; Kumar D; Snyder V; Arnold L; Nissen E; Hu Q; Cheng N; Miller D; Thomas AR; Shnayder Y; Kakarala K; Tsue TT; Girod DA; Thomas SM
Sci Rep; 2018 Aug; 8(1):12163. PubMed ID: 30111862
[TBL] [Abstract][Full Text] [Related]
26. Valproate augments Niraparib killing of tumor cells.
Booth L; Roberts JL; Rais R; Poklepovic A; Dent P
Cancer Biol Ther; 2018; 19(9):797-808. PubMed ID: 29923797
[TBL] [Abstract][Full Text] [Related]
27. Curcumin interacts with sildenafil to kill GI tumor cells via endoplasmic reticulum stress and reactive oxygen/ nitrogen species.
Roberts JL; Poklepovic A; Booth L
Oncotarget; 2017 Nov; 8(59):99451-99469. PubMed ID: 29245915
[TBL] [Abstract][Full Text] [Related]
28. The novel synthetic oleanane triterpenoid CDDO (2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid) induces apoptosis in Mycosis fungoides/Sézary syndrome cells.
Zhang C; Ni X; Konopleva M; Andreeff M; Duvic M
J Invest Dermatol; 2004 Aug; 123(2):380-7. PubMed ID: 15245439
[TBL] [Abstract][Full Text] [Related]
29. Systematic review of combination therapies for mycosis fungoides.
Humme D; Nast A; Erdmann R; Vandersee S; Beyer M
Cancer Treat Rev; 2014 Sep; 40(8):927-33. PubMed ID: 24997678
[TBL] [Abstract][Full Text] [Related]
30. Possible effects of plasminogen activator inhibitor-1 on promoting angiogenesis through matrix metalloproteinase 9 in advanced mycosis fungoides.
Fujimura T; Ohuchi K; Ikawa T; Kambayashi Y; Amagai R; Furudate S; Asano Y
Hematol Oncol; 2024 Jan; 42(1):e3244. PubMed ID: 38287534
[TBL] [Abstract][Full Text] [Related]
31. Long-term control of mycosis fungoides of the hands with topical bexarotene.
Lain T; Talpur R; Duvic M
Int J Dermatol; 2003 Mar; 42(3):238-41. PubMed ID: 12653924
[TBL] [Abstract][Full Text] [Related]
32. Axitinib and HDAC Inhibitors Interact to Kill Sarcoma Cells.
Roberts JL; Booth L; Poklepovic A; Dent P
Front Oncol; 2021; 11():723966. PubMed ID: 34604061
[TBL] [Abstract][Full Text] [Related]
33. Identification of Signaling Pathways by Which CD40 Stimulates Autophagy and Antimicrobial Activity against Toxoplasma gondii in Macrophages.
Liu E; Lopez Corcino Y; Portillo JA; Miao Y; Subauste CS
Infect Immun; 2016 Sep; 84(9):2616-26. PubMed ID: 27354443
[TBL] [Abstract][Full Text] [Related]
34. PDE5 inhibitors enhance the lethality of pemetrexed through inhibition of multiple chaperone proteins and via the actions of cyclic GMP and nitric oxide.
Booth L; Roberts JL; Poklepovic A; Gordon S; Dent P
Oncotarget; 2017 Jan; 8(1):1449-1468. PubMed ID: 27903966
[TBL] [Abstract][Full Text] [Related]
35. BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing.
Martin AP; Park MA; Mitchell C; Walker T; Rahmani M; Thorburn A; Häussinger D; Reinehr R; Grant S; Dent P
Mol Pharmacol; 2009 Aug; 76(2):327-41. PubMed ID: 19483105
[TBL] [Abstract][Full Text] [Related]
36. Abrus Agglutinin, a type II ribosome inactivating protein inhibits Akt/PH domain to induce endoplasmic reticulum stress mediated autophagy-dependent cell death.
Panda PK; Behera B; Meher BR; Das DN; Mukhopadhyay S; Sinha N; Naik PP; Roy B; Das J; Paul S; Maiti TK; Agarwal R; Bhutia SK
Mol Carcinog; 2017 Feb; 56(2):389-401. PubMed ID: 27182794
[TBL] [Abstract][Full Text] [Related]
37. Treatment of mycosis fungoides with oral bexarotene combined with PUVA.
Stern DK; Lebwohl M
J Drugs Dermatol; 2002 Sep; 1(2):134-6. PubMed ID: 12847736
[TBL] [Abstract][Full Text] [Related]
38. [Granulomatous mycosis fungoides: combination therapy with bexarotene and PUVA].
Wirtz M; Helbig D
Hautarzt; 2014 Apr; 65(4):274-6. PubMed ID: 24671704
[TBL] [Abstract][Full Text] [Related]
39. [Treatment of mycosis fungoides with PUVA and bexarotene].
Ortiz-Romero PL; Sánchez-Largo ME; Sanz H; García-Romero D; Rosales B; Valverde R; Arrue I; Polo I; Ruiz D; Fernández-Herrera J; Vanaclocha F
Actas Dermosifiliogr; 2006 Jun; 97(5):311-8. PubMed ID: 16956562
[TBL] [Abstract][Full Text] [Related]
40. Disease characteristics, prognosis, and response to therapy in patients with large-cell transformed mycosis fungoides: A single-center retrospective study.
O'Donnell M; Zaya R; Correia E; Krishnasamy S; Sahu J; Shi W; Cha J; Alpdogan SO; Porcu P; Nikbakht N
J Am Acad Dermatol; 2022 Jun; 86(6):1285-1292. PubMed ID: 34273458
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
